Cobra Reduce

STUDY IDENTIFIER:

Cobra Reduce

CONDITION:

Angina and CAD (Coronary Artery Disease)

CONTACT INFO:

Rose Peterson, RN   |   Rose.Peterson@allina.com   |   612-863-6051

DESCRIPTION:

The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, receiving the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) have a higher safety and non-inferior outcome for thrombo-embolic events compared to patients receiving the standard FDA-approved drug eluting stent (DES) plus 6-month DAPT.

CRITERIA LIST/ QUALIFICATIONS:

  • Ischemic symptoms (stable or unstable angina) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels.
  • Patient receiving or with an indication for new treatment with long-term oral anticoagulation with a coumadin derivatives or non-vitamin K oral anticoagulants.

INVESTIGATORS:

Daniel Lips, MD

SPONSORS:

CeloNova BioSciences, Inc.

STATUS:

Open/Enrolling